EpMab-16 (mouse IgG2a) for EpCAM also demonstrated significant antitumor activity against colon cancer xenograft models (31), and oral squamous cell carcinomas (33). This evidence concerns the gene EPCAM and oral cavity squamous cell carcinoma.